skip to Main Content

What sets us apart from our peers is our single focus on developing potent and conditionally active T cell targeted immunotherapies for solid tumor cancers with increased tumor specificity and reduced toxicity.

Our COBRA™ pipeline features proprietary and patented conditionally active T cell engaging molecules that we are rapidly accelerating towards the clinic.

no image

(pipeline graphic placeholder)

Back To Top